Brief: HLS Therapeutics Becomes Exclusive Canadian Distributor For Mycare Insite Point-Of-Care Device
01/06/2020 11:35
June 1 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS - HAS BECOME EXCLUSIVE CANADIAN
DISTRIBUTOR FOR
MYCARE INSITE POINT-OF-CARE DEVICE
* HLS THERAPEUTICS - HAS BECOME EXCLUSIVE CANADIAN
DISTRIBUTOR FOR
MYCARE RELATED LINE OF DIAGNOSTIC TESTS FROM SALADAX BIOMEDICAL
Source text for Eikon: ID:nCNWLp3WTa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease